Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy

Diabetes Care

Volumn 29, Issue 4, 2006, Pages 848-852

  Konoshita, Tadashi ^a   Wakahara, Shigeyuki ^a   Mizuno, Shinichi ^a   Motomura, Makoto ^a   Aoyama, Chikako ^a   Makino, Yasukazu ^a   Kawai, Yasuyuki ^a   Kato, Norihiro ^b   Koni, Ichiro ^c   Miyamori, Isamu ^a   Mabuchi, Hiroshi ^c  

^a UNIVERSITY OF FUKUI   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOGLOBULIN G; RENIN; RNA;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ANALYSIS; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; KIDNEY CORTEX SLICE; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

EID: 33746368725     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.04.06.dc05-1873     Document Type: Article

References (32)

1. Hostetter TH: Hyperfiltration and glomerulosclerosis. Semin Nephrol 23:194-199, 2003
2. Haneda M, Koya D, Isono M, Kikkawa R: Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14:1374-1382, 2003
3. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268, 2001
4. Wolf G: New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34:785-796, 2004
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
6. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria: the EUCLID Study Group. Lancet 349:1787-1792, 1997
7. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 355:253-259, 2000
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
10. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
11. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672-678, 2002
12. Miller JA, Floras JS, Zinman B, Skorecki KL, Logan AG: Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci (Lond) 90:189-195, 1996
13. Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, Price DA, Laffel LM, Williams GH, Fisher ND: Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 65:1435-1439, 2004
14. Christlieb AR, Kaldany A, D'Elia JA: Plasma renin activity and hypertension in diabetes mellitus. Diabetes 25:969-974, 1976
15. Perez GO, Lespier L, Jacobi J, Oster JR, Katz FH, Vaamonde CA, Fishman LM: Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 137:852-855, 1977
16. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109:1417-1427, 2002
17. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM: Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature 417:822-828, 2002
18. Largo R, Gomez-Garre D, Soto K, Marron B, Blanco J, Gazapo RM, Plaza JJ, Egido J: Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 33:732-739, 1999
19. Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG, Burns KD: Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 58:2320-2330, 2000
20. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114:1128-1135, 2004
21. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL: Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int 56:211-221, 1999
22. Vallon V, Wead LM, Blantz RC: Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: effect of sodium and salt restriction. J Am Soc Nephrol 5:1761-1767, 1995
23. Everett AD, Scott J, Wilfong N, Marino B, Rosenkranz RP, Inagami T, Gomez RA: Renin and angiotensinogen expression during the evolution of diabetes. Hypertension 19:70-78, 1992
24. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265:F477-F486, 1993
25. Kalinyak JE, Sechi LA, Griffin CA, Don BR, Tavangar K, Kraemer FB, Hoffman AR, Schambelan M: The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 4:1337-1345, 1993
26. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME: Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41:392-397, 2003
27. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD: Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 280:F254-F265, 2001
28. Bonnet F, Candido R, Carey RM, Casley D, Russo LM, Osicka TM, Cooper ME, Cao Z: Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. J Hypertens 20:1615-1624, 2002
29. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M, Egido J: Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 84:S64-S70, 2003
30. Mizuiri S, Yoshikawa H, Tanegashima M, Miyagi M, Kobayashi M, Sakai K, Hayashi I, Aikawa A, Ohara T, Hasegawa A: Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 31:301-307, 1998
31. Wagner J, Gehlen F, Ciechanowicz A, Ritz E: Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 10:545-551, 1999
32. Choi KC, Kim NH, An MR, Kang DG, Kim SW, Lee J: Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int Suppl 60:S23-S27, 1997